NR1H4 and metabolic dysfunction-associated steatohepatitis: A phase 2 clinical trial in NASH patients exploring the efficacy of a combination of Tropifexor (LJN452, an FXR agonist) and Cenicriviroc has been completed, and the results are pending publication (NCT03517540).